GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial
Open Access
- 8 April 2026
- journal article
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (4) , 102743
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation statusObesity, 2025
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or ObesityJAMA Network Open, 2025
- One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical PracticeJAMA Network Open, 2024
- Tirzepatide for Weight Reduction in Chinese Adults With ObesityJAMA, 2024
- Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort studyObesity, 2023
- Obesity Management in AdultsJAMA, 2023
- GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal modelsEuropean Journal of Pharmacology, 2022
- Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)Diabetes Therapy, 2021
- ObesityJACC, 2018
- Adherence to Therapies in Patients with Type 2 DiabetesDiabetes Therapy, 2013